基石药业-B（02616.HK）今日盘中大涨5.42%，引发市场关注。截至发稿，该股报5.94港元，创下近17个月新高。
消息面上，基石药业今日宣布与欧洲知名生物医药公司Istituto Gentili就其重磅产品舒格利单抗在西欧和英国的商业化达成独家战略合作。根据协议，Gentili将获得舒格利单抗在23个欧洲国家的独家商业化权利，涵盖18个欧洲经济区国家以及英国等。作为回报，基石药业将获得最高1.925亿美元的里程碑付款，以及授权区域内舒格利单抗近50%净销售额的营收分成。
分析人士认为，这项合作有望加速舒格利单抗在欧洲市场的商业化进程，显著扩大产品的国际市场覆盖。舒格利单抗是首个在欧盟及英国获批用于联合化疗一线治疗IV期非小细胞肺癌全人群的PD-L1单抗，具有重要的临床价值。此次战略合作不仅为基石药业带来可观的潜在收益，也标志着公司国际化战略取得重要突破，因此受到投资者积极追捧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.